Connor, Clark & Lunn Investment Management Ltd. X4 Pharmaceuticals, Inc Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$0.89 - $1.71 $20,527 - $39,441	23,065 New	23,065 $39,000
Q1 2022 May 12, 2022	SELL	$1.48 - $2.58 $18,923 - $32,987	-12,786 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$1.9 - $5.6 $24,293 - $71,601	12,786 New	12,786 $29,000

Others Institutions Holding XFOR

# of Institutions

105

Shares Held

100M

Call Options Held

213K

Put Options Held

50.6K

Bain Capital Life Sciences Investors, LLC Boston, MA

16.9M
Shares

$5.75 Million
2.03% of portfolio
Nea Management Company, LLC Timonium, MD

15M
Shares

$5.1 Million
0.77% of portfolio
Black Rock Inc. New York, NY

10.7M
Shares

$3.63 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

8.44M
Shares

$2.87 Million
0.0% of portfolio
Orbimed Advisors LLC San Diego, CA

7.13M
Shares

$2.43 Million
0.11% of portfolio

View Full List

About X4 Pharmaceuticals, Inc

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $23.3M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

More about XFOR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account